Difference between revisions of "Polatuzumab vedotin (Polivy)"
Jump to navigation
Jump to search
m |
m |
||
Line 6: | Line 6: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Diffuse large B-cell lymphoma]] | *[[Diffuse large B-cell lymphoma]] | ||
− | + | *[[High-grade B-cell lymphoma]] | |
==Patient drug information== | ==Patient drug information== | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*2019-06-10: Accelerated approval in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory [[diffuse large B-cell lymphoma|diffuse large B-cell lymphoma (DLBCL), not otherwise specified]], after at least two prior therapies. ''(Based on GO29365)'' | *2019-06-10: Accelerated approval in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory [[diffuse large B-cell lymphoma|diffuse large B-cell lymphoma (DLBCL), not otherwise specified]], after at least two prior therapies. ''(Based on GO29365)'' | ||
+ | *2023-04-19: Approved with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients who have previously untreated [[diffuse large B-cell lymphoma|diffuse large B-cell lymphoma (DLBCL)]], not otherwise specified (NOS), or [[High-grade B-cell lymphoma|high-grade B-cell lymphoma (HGBL)]] and who have an International Prognostic Index (IPI) score of 2 or greater. ''(Based on POLARIX)'' | ||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
*2020-01-16: Initial conditional approval | *2020-01-16: Initial conditional approval | ||
Line 33: | Line 34: | ||
[[Category:Diffuse large B-cell lymphoma medications]] | [[Category:Diffuse large B-cell lymphoma medications]] | ||
+ | [[Category:High-grade B-cell lymphoma medications]] | ||
[[Category:FDA approved in 2019]] | [[Category:FDA approved in 2019]] | ||
[[Category:EMA approved in 2020]] | [[Category:EMA approved in 2020]] | ||
[[Category:Health Canada approved in 2020]] | [[Category:Health Canada approved in 2020]] | ||
[[Category:Genentech product]] | [[Category:Genentech product]] |
Revision as of 16:36, 20 April 2023
General information
Class/mechanism from the NCI Drug Dictionary: An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against B-cell antigen receptor complex-associated protein beta chain (CD79B) conjugated, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity. Upon administration, polatuzumab vedotin selectively binds to CD79B, a protein which is abundantly expressed on the surface of B-cells. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis.
Route: IV
Extravasation: neutral
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 2019-06-10: Accelerated approval in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies. (Based on GO29365)
- 2023-04-19: Approved with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. (Based on POLARIX)
History of changes in EMA indication
- 2020-01-16: Initial conditional approval
History of changes in Health Canada indication
- 2020-07-09: Initial notice of compliance with conditions
- 2023-01-20: Conditions were met
Also known as
- Code name: DCDS4501A
- Generic name: polatuzumab vedotin-piiq
- Brand name: Polivy